Showing 3511-3520 of 9334 results for "".
Busy by Design Plans: How to Use Downtime to Drive Revenue and Make Uptime Smoother for Your Team
https://practicaldermatology.com/issues/september-2025/busy-by-design-plans-how-to-use-downtime-to-drive-revenue-and-make-uptime-smoother-for-your-team/37641/In today’s fast-paced dermatology industry, treatments can sometimes feel more transactional than transformational.Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.Structure: The Backbone of a Practice Transaction
https://practicaldermatology.com/topics/practice-management/structure-the-backbone-of-a-practice-transaction/23961/Practice Management to Stay Competitive and Happy
https://practicaldermatology.com/topics/practice-management/practice-management-to-stay-competitive-and-happy/23956/Close Up With Mikkel Østergaard, MD, PhD, DMSc
https://practicaldermatology.com/topics/close-up/close-up-with-mikkel-ostergaard-md-phd-dmsc/23941/Close Up with Eric F. Bernstein, MD
https://practicaldermatology.com/topics/close-up/close-up-with-eric-f-bernstein-md/23928/Letter to the Editor
https://practicaldermatology.com/columns/letter-to-the-editor/letter-to-the-editor-3/23917/Lose Your Inhibitions: Expanding Use of JAK Inhibitors
https://practicaldermatology.com/topics/atopic-dermatitis/lose-your-inhibitions-expanding-use-of-jak-inhibitors/23910/Despite data on safety concerns, dermatologists and patients see benefits.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-45/23890/Redefining the Discourse: Psoriasis in Diverse Skin Tones
https://practicaldermatology.com/topics/psoriasis/redefining-the-discourse-psoriasis-in-diverse-skin-tones/23856/A lack of representation for underserved ethno-racial groups in clinical data and research is an underlying factor contributing to physicians’ challenges with effectively diagnosing and treating psoriasis in patients with diverse skin tones.